Quarterly report pursuant to Section 13 or 15(d)

Merger and Contingent Value Rights Agreement (Details)

v3.22.1
Merger and Contingent Value Rights Agreement (Details)
3 Months Ended
Mar. 31, 2022
Milestone
Sep. 30, 2021
Milestone
Jun. 30, 2021
Milestone
Nov. 05, 2020
Right
Contingent Value Rights Agreement [Abstract]        
Contingent value rights payment period 15 years      
Sum of cash consideration paid by a third party       75.00%
Parent IP deal period 10 years      
Number of milestones accrued 0      
Number of potential milestones   0 0  
Rexahn [Member]        
Contingent Value Rights Agreement [Abstract]        
Number of contingent value right received per common stock | Right       1
Rexahn [Member] | BioSense Global LLC [Member]        
Contingent Value Rights Agreement [Abstract]        
Percentage of payments received by Rexahn or its affiliates       90.00%
Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member]        
Contingent Value Rights Agreement [Abstract]        
Percentage of payments received by Rexahn or its affiliates       90.00%